Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder
Public ClinicalTrials.gov record NCT00099229. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Tolerability of Licarbazepine 1000-2000mg/Day in the Treatment of Manic Episodes of Bipolar I Disorder Over 3 Weeks
Study identification
- NCT ID
- NCT00099229
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 320 participants
Conditions and interventions
Conditions
Interventions
- Licarbazepine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 31, 2004
- Primary completion
- Jul 31, 2006
- Completion
- Jul 31, 2006
- Last update posted
- Feb 22, 2017
2004 – 2006
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site | Little Rock | Arkansas | 72211 | — |
| Investigational Site | Cerritos | California | 90703 | — |
| Investigational Site | San Diego | California | 92126 | — |
| Investigational Site | Port Charlotte | Florida | 33952 | — |
| Investigational Site | Indianapolis | Indiana | 46222 | — |
| Investigational Site | Newton | Kansas | 67114 | — |
| Investigational Site | Las Vegas | Nevada | 89103 | — |
| Investigational Site | Raleigh | North Carolina | 27609 | — |
| Investigational Site | Cincinnati | Ohio | 45267 | — |
| Investigational Site | Oklahoma City | Oklahoma | 73118 | — |
| Investigational Site | Philadelphia | Pennsylvania | 19124 | — |
| Investigational Site | Austin | Texas | 78756 | — |
| Investigational Site | Bellaire | Texas | 77401 | — |
| Investigational Site | Houston | Texas | 77007 | — |
| Investigational Site | Houston | Texas | 77021 | — |
| Investigational Site | Kirkland | Washington | 98033 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00099229, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 22, 2017 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00099229 live on ClinicalTrials.gov.